LCT (ASX: LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases by discovering, developing and commercialising novel treatments for debilitating conditions. Product candidates include NTCELL, an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells targeting Parkinson’s disease. LCT is listed on the Australian (ASX: LCT) and US (OTCQB: LVCLY) stock exchanges and is incorporated in Australia, with operations based in New Zealand